Nova Cells Institute has never worked with embryonic or fetal stem cells, and never will. Embryonic and fetal stem cells can produce tumors (These are classified as pluripotent” which means they can form teratomas and other tumors in certain instances such as being injected into the central nervous system). The adult stem cells Nova Cells uses (umbilical cord, Wharton’s Jelly, placenta-derived, and a patient’s own bone marrow) are “multipotent” which limits the body cell types they can become (These stem cells do not form teratomas or such. Some private stem cell clinics in Europe and the US have injected adult stem cells into organs such as kidneys and eyes which caused problems and complications. Nova Cells Institute has never injected stem cells into an organ).
Let’s be very clear about these points and a few others:
(1) Nova Cells was established in 2009. There are other companies that came along later on which use “Nova” in their company title, but these are NOT affiliated in any way with Nova Cells Institute of Mexico (NCIM).
(2) Nova Cells Institute has never used embryonic or fetal stem cells and never will (They can form tumors under certain circumstances).
(3) Nova Cells Institute only uses multipotent adult stem cells derived from umbilical cord blood, Wharton’s Jelly, placental tissue, and a patient’s own bone marrow.
(4) Nova Cells Institute administers stem cells by intravenous drip (On rare occasions Nova Cells affiliated doctors recommend an intrathecal or spinal tap infusion of cells. Everything related to this is spelled out, a process called “informed consent”. Patients who prefer not to do this are given cells by intravenous or IV drip).
On Wednesday, 1-18-2017 Nova Cell’s (NCIM) patient educator & care coordinator, Grace Odgers, PhD cand., was interviewed by Denise Messenger on Blog Talk Radio concerning NCIMs unique stem cell medicine program. You can access an audio of this 42m31s minute interview by clicking the link below.
Nova Cells Institute of Mexico contracted MDs treat children and adults with umbilical cord blood stem cells and in some instances a patient’s own bone marrow stem cells. MDs who work with Nova Cells also administer its proprietary “Beacon Factor“, a nontoxic compound that greatly enhances stem cell homing, improves circulation, reduces inflammation, improves nerve signal transmission, and steps up the processing of intracellular “junk” by lysosomes (The cells “garbage disposal” system whose malfunctioning is linked to all kinds of neurodegenerative diseases and conditions).
Nova Cells uses only certifiably disease free umbilical cord stem cells and those from Wharton’s Jelly, and sometimes a patient’s own bone marrow stem cells, all of which are processed in Mexico in a state-of-the-art laboratory run by our firm’s director of laboratory services, Dr. Abel Pena (Photo above).
Dr. Pena, who is a biochemist, was trained by a leading US stem cell biologist and maintains the highest levels of safety and hygiene in his lab in Tijuana. In addition, he has pioneered numerous methods for priming stem cells; that is, getting them to respond to chemical signals in target tissues by becoming cells that tend to effect or support healing or relief. Stem cells primed using his methods have produced impressive, sometimes remarkable clinical responses in people with a wide variety of neurologic & other diseases and conditions.
CONTACT: Grace Odgers, PhD cand. – Program educator and patient care coordinator
Phone: 1-562- 916-3410 E-mail: firstname.lastname@example.org
ADVANTAGES OF WHARTON’S JELLY STEM CELLS ESPECIALLY MESENCYMALS (Designated as WJ-MSC for convenience below) ESPECIALLY WITH RESPECT TO SAFETY
WJ HAS MORE STEM CELLS THAN EITHER BONE MARROW OR ADIPOSE TISSUE
The quantity of mesenchymal stem cells which can typically be obtained from bone marrow is far less than that Wharton’s Jelly: 0.001 to 0.01% mononuclear cells from BM, with 1 g of adipose tissue yielding ~ 5 × 103 stem cells, and Wharton’s jelly 1 to 5 × 104 cells/cm of umbilical cord. In side-by-side comparison studies of MSC from bone marrow adipose tissue and Wharton’s jelly, WJ-MSCs had the highest proliferative capacity.
WJ STEM CELLS ARE MORE PRIMITIVE THAN OTHER ADULT STEM CELL TYPES YET DO NOT PRODUCE TUMORS AND ACTUALLY HAVE ANTI-TUMOR EFFECTS IN VITRO (Lab dish) AND IN VIVO (In living animals & humans)
WJ-MSC differ from other adult MSCs with respect to the fact they demonstrate far more primitive characteristics e.g., they express embryonic-like stem cell markers including pluripotency genes, Oct-4, Nanog, and SOX-2 but at levels well below that of embryonic stem (ESC) cells. Despite this, WJ-MSCs do not form tumors (teratomas). This is attributed to the fact that WJ-MS’s have a lower expression of pluripotency genes than embryonic stem cells (ESCs being very pluripotent and by virtue of this are prone to develop teratomas when injected into animals or humans). When WJ-MSCs were injected in immunocompromised and immunodeficient animals they still failed to form tumors.
Also: WJ-MSCs express low levels of the embryonic stem cell pluripotency markers POUF1, NANOG, SOX2 and LIN28, which also plays a role in the fact they do not produce teratomas. WJ-MSCs also synthesize and express several cytokines including IL12A which is associated with the induction of apoptosis (programmed cell death) which is believed to underlie their ability to lyse (eradicate) tumor cells.
Furthermore, the transcriptome of WJ-MSC and ESC differs substantially in that WJ-MSCs demonstrate high expression levels of several tumor suppressor genes and suppresses tumors both in vitro and in vivo. Moreover, large quantities of tumor growth inhibiting cytokines and growth factors are secreted by WJ-MSCs. Also, WJ-MSC cell lysates as well as the conditioned medium they are cultured in strongly inhibited the growth of breast adenocarcinoma, ovarian carcinoma, osteosarcoma, benign neoplastic keloid cells, bladder tumor, and lymphoma cells in vitro. When WJ-MSC cell lysates and conditioned medium were injected into mammary carcinoma, osteosarcoma, and pancreatic and lung tumors it inhibited their growth and shrank the tumors in vivo .
WJ-MSCs DO NOT CAUSE IMMUNE REJECTION OR ADVERSE REACTIONS
WJ-MSCs have also been found to be immunoprivileged which is to say they escape rejection or adverse immune reactions. Part of the reason for this lies in the fact WJ-MSCs have low MHC-I levels and an absence of MHC-II expression. And, though they synthesize low amounts of MHC class I, WJ-MSCs have no immunogenicity. Research indicates that this is due to the fact they do not express costimulatory molecules such as CD 40, CD80, CD86, and also produce high levels of immune response inhibitors such as indoleamine-2,3-dioxygenase (IDO), prostaglandin E2 (PGE2) and leukocyte antigen G6 (HLA-G6).
NOVA CELLS INSTITUTE HARVESTS & MAKES CLINICAL USE OF STEM CELLS ISOLATED FROM (UMBILICAL CORD) WHARTON’S JELLY CELLS: https://ncimx.wordpress.com/2015/03/15/whartons-jelly-stem-cells/
ADDITIONAL REFERENCES – NIH PubMed results (5-1-2016)
|Wharton’s Jelly-derived mesenchymal stem cells alleviate memory deficits and reduce amyloid-β deposition in an APP/PS1 transgenic mouse model.|
|Xie ZH, Liu Z, Zhang XR, Yang H, Wei LF, Wang Y, Xu SL, Sun L, Lai C, Bi JZ, Wang XY.|
|Clin Exp Med. 2016 Feb;16(1):89-98. doi: 10.1007/s10238-015-0375-0. Epub 2015 Jul 19.|
|PMID: 26188488 [PubMed – in process]|
|Therapeutic influence of intraperitoneal injection of Wharton’s jelly-derived mesenchymal stem cells on oviduct function and fertility in rats with acute and chronic salpingitis.|
|Luo HJ, Xiao XM, Zhou J, Wei W.|
|Genet Mol Res. 2015 Apr 17;14(2):3606-17. doi: 10.4238/2015.April.17.10.|
|PMID: 25966129 [PubMed – indexed for MEDLINE] Free Article|
|Effect of human Wharton’s jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells.|
|Hendijani F, Javanmard ShH, Rafiee L, Sadeghi-Aliabadi H.|
|Res Pharm Sci. 2015 Mar-Apr;10(2):134-42.|
|PMID: 26487890 [PubMed] Free PMC Article|
|Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells.|
|Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K.|
|Diabetes. 2015 Feb;64(2):587-92. doi: 10.2337/db14-0656. Epub 2014 Sep 9.|
|PMID: 25204974 [PubMed – indexed for MEDLINE] Free Article|
|.||The Potential of Wharton’s Jelly Derived Mesenchymal Stem Cells in Treating Patients with Cystic Fibrosis.|
|Boruczkowski D, Gładysz D, Demkow U, Pawelec K.|
|Adv Exp Med Biol. 2015;833:23-9. doi: 10.1007/5584_2014_17. Review.|
|PMID: 25248343 [PubMed – indexed for MEDLINE]|
|Wharton’s jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance.|
|Kalaszczynska I, Ferdyn K.|
|Biomed Res Int. 2015;2015:430847. doi: 10.1155/2015/430847. Epub 2015 Mar 15. Review.|
|PMID: 25861624 [PubMed – indexed for MEDLINE] Free PMC Article|
|Undifferentiated Wharton’s Jelly Mesenchymal Stem Cell Transplantation Induces Insulin-Producing Cell Differentiation and Suppression of T-Cell-Mediated Autoimmunity in Nonobese Diabetic Mice.|
|Tsai PJ, Wang HS, Lin GJ, Chou SC, Chu TH, Chuan WT, Lu YJ, Weng ZC, Su CH, Hsieh PS, Sytwu HK, Lin CH, Chen TH, Shyu JF.|
|Cell Transplant. 2015;24(8):1555-70. doi: 10.3727/096368914X683016. Epub 2014 Jul 15.|
|PMID: 25198179 [PubMed – in process]|
|Effects of Wharton’s jelly-derived mesenchymal stem cells on neonatal neutrophils.|
|Khan I, Zhang L, Mohammed M, Archer FE, Abukharmah J, Yuan Z, Rizvi SS, Melek MG, Rabson AB, Shi Y, Weinberger B, Vetrano AM.|
|J Inflamm Res. 2014 Dec 31;8:1-8. doi: 10.2147/JIR.S71987. eCollection 2015.|
|PMID: 25678809 [PubMed] Free PMC Article|
|A comparison of Wharton’s jelly and cord blood as a source of mesenchymal stem cells for diabetes cell therapy.|
|El-Demerdash RF, Hammad LN, Kamal MM, El Mesallamy HO.|
|Regen Med. 2015;10(7):841-55. doi: 10.2217/rme.15.49. Epub 2015 Nov 6.|
|PMID: 26541176 [PubMed – in process]|
|.||Comparisons of Differentiation Potential in Human Mesenchymal Stem Cells from Wharton’s Jelly, Bone Marrow, and Pancreatic Tissues.|
|Kao SY, Shyu JF, Wang HS, Lin CH, Su CH, Chen TH, Weng ZC, Tsai PJ.|
|Stem Cells Int. 2015;2015:306158. doi: 10.1155/2015/306158. Epub 2015 Jul 29.|
|PMID: 26294917 [PubMed] Free PMC Article|
|.||Roles of the co-culture of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells with rat pancreatic cells in the treatment of rats with diabetes mellitus.|
|Wang G, Li Y, Wang Y, Dong Y, Wang FS, Ding Y, Kang Y, Xu X.|
|Exp Ther Med. 2014 Nov;8(5):1389-1396. Epub 2014 Sep 22.|
|PMID: 25289028 [PubMed] Free PMC Article|
|Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation.|
|Li X, Bai J, Ji X, Li R, Xuan Y, Wang Y.|
|Int J Mol Med. 2014 Sep;34(3):695-704. doi: 10.3892/ijmm.2014.1821. Epub 2014 Jun 25.|
|PMID: 24970492 [PubMed – indexed for MEDLINE] Free PMC Article|
|Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy.|
|Woodworth TG, Furst DE.|
|Arthritis Res Ther. 2014 Jul 30;16(4):113. doi: 10.1186/ar4677.|
|PMID: 25166210 [PubMed – indexed for MEDLINE] Free PMC Article|
|A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus.|
|Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, Hua R, Niu X, Shi J, An Y.|
|Stem Cell Res Ther. 2014 Apr 23;5(2):57. doi: 10.1186/scrt446.|
|PMID: 24759263 [PubMed – indexed for MEDLINE] Free PMC Article|
|Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jelly.|
|Amable PR, Teixeira MV, Carias RB, Granjeiro JM, Borojevic R.|
|Stem Cell Res Ther. 2014 Apr 16;5(2):53. doi: 10.1186/scrt442.|
|PMID: 24739658 [PubMed – indexed for MEDLINE] Free PMC Article|
|Therapeutic effect of transplanted human Wharton’s jelly stem cell-derived oligodendrocyte progenitor cells (hWJ-MSC-derived OPCs) in an animal model of multiple sclerosis.|
|Mikaeili Agah E, Parivar K, Joghataei MT.|
|Mol Neurobiol. 2014 Apr;49(2):625-32. doi: 10.1007/s12035-013-8543-2. Epub 2013 Aug 28.|
|PMID: 23982748 [PubMed – indexed for MEDLINE]|
|Microvesicles derived from human Wharton’s Jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1.|
|Zou X, Zhang G, Cheng Z, Yin D, Du T, Ju G, Miao S, Liu G, Lu M, Zhu Y.|
|Stem Cell Res Ther. 2014 Mar 19;5(2):40. doi: 10.1186/scrt428.|
|PMID: 24646750 [PubMed – indexed for MEDLINE] Free PMC Article|
|.||Effect of combined therapy of human Wharton’s jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats.|
|Hu J, Wang F, Sun R, Wang Z, Yu X, Wang L, Gao H, Zhao W, Yan S, Wang Y.|
|Endocrine. 2014 Mar;45(2):279-87. doi: 10.1007/s12020-013-9984-0. Epub 2013 May 18.|
|PMID: 23686639 [PubMed – indexed for MEDLINE]|
|Effect of human Wharton’s jelly mesenchymal stem cell paracrine signaling on keloid fibroblasts.|
|Arno AI, Amini-Nik S, Blit PH, Al-Shehab M, Belo C, Herer E, Jeschke MG.|
|Stem Cells Transl Med. 2014 Mar;3(3):299-307. doi: 10.5966/sctm.2013-0120. Epub 2014 Jan 16.|
|PMID: 24436441 [PubMed – indexed for MEDLINE] Free PMC Article|
|Human Wharton’s jelly mesenchymal stem cells promote skin wound healing through paracrine signaling.|
|Arno AI, Amini-Nik S, Blit PH, Al-Shehab M, Belo C, Herer E, Tien CH, Jeschke MG.|
|Stem Cell Res Ther. 2014 Feb 24;5(1):28. doi: 10.1186/scrt417.|
|PMID: 24564987 [PubMed – indexed for MEDLINE] Free PMC Article|
|.||Characterization of hepatic markers in human Wharton’s Jelly-derived mesenchymal stem cells.|
|Buyl K, De Kock J, Najar M, Lagneaux L, Branson S, Rogiers V, Vanhaecke T.|
|Toxicol In Vitro. 2014 Feb;28(1):113-9. doi: 10.1016/j.tiv.2013.06.014. Epub 2013 Jun 29.|
|PMID: 23820183 [PubMed – indexed for MEDLINE]|
|Human Wharton’s Jelly Mesenchymal Stem Cells plasticity augments scar-free skin wound healing with hair growth.|
|Sabapathy V, Sundaram B, V M S, Mankuzhy P, Kumar S.|
|PLoS One. 2014 Apr 15;9(4):e93726. doi: 10.1371/journal.pone.0093726. eCollection 2014.|
|PMID: 24736473 [PubMed – indexed for MEDLINE] Free PMC Article|
|Stem cells from umbilical cord Wharton’s jelly from preterm birth have neuroglial differentiation potential.|
|Messerli M, Wagner A, Sager R, Mueller M, Baumann M, Surbek DV, Schoeberlein A.|
|Reprod Sci. 2013 Dec;20(12):1455-64. doi: 10.1177/1933719113488443. Epub 2013 May 13.|
|PMID: 23670950 [PubMed – indexed for MEDLINE] Free PMC Article|
|Wharton’s jelly-derived mesenchymal stem cells promote myocardial regeneration and cardiac repair after miniswine acute myocardial infarction.|
|Zhang W, Liu XC, Yang L, Zhu DL, Zhang YD, Chen Y, Zhang HY.|
|Coron Artery Dis. 2013 Nov;24(7):549-58. doi: 10.1097/MCA.0b013e3283640f00.|
|PMID: 23892469 [PubMed – indexed for MEDLINE]|
|Reduction of fibrosis in dibutyltin dichloride-induced chronic pancreatitis using rat umbilical mesenchymal stem cells from Wharton’s jelly.|
|Zhou CH, Li ML, Qin AL, Lv SX, Wen-Tang, Zhu XY, Li LY, Dong Y, Hu CY, Hu DM, Wang SF.|
|Pancreas. 2013 Nov;42(8):1291-302. doi: 10.1097/MPA.0b013e318296924e.|
|PMID: 24152954 [PubMed – indexed for MEDLINE]|
|Human Wharton’s jelly-derived mesenchymal stromal cells reduce renal fibrosis through induction of native and foreign hepatocyte growth factor synthesis in injured tubular epithelial cells.|
|Du T, Zou X, Cheng J, Wu S, Zhong L, Ju G, Zhu J, Liu G, Zhu Y, Xia S.|
|Stem Cell Res Ther. 2013 Jun 4;4(3):59. doi: 10.1186/scrt215.|
|PMID: 23734757 [PubMed – indexed for MEDLINE] Free PMC Article|
|Higher propensity of Wharton’s jelly derived mesenchymal stromal cells towards neuronal lineage in comparison to those derived from adipose and bone marrow.|
|Balasubramanian S, Thej C, Venugopal P, Priya N, Zakaria Z, Sundarraj S, Majumdar AS.|
|Cell Biol Int. 2013 May;37(5):507-15. doi: 10.1002/cbin.10056. Epub 2013 Feb 18.|
|PMID: 23418097 [PubMed – indexed for MEDLINE]|
|Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton’s jelly and umbilical cord.|
|Manochantr S, U-pratya Y, Kheolamai P, Rojphisan S, Chayosumrit M, Tantrawatpan C, Supokawej A, Issaragrisil S.|
|Intern Med J. 2013 Apr;43(4):430-9. doi: 10.1111/imj.12044.|
|PMID: 23176558 [PubMed – indexed for MEDLINE]|
|.||Mesenchymal stem cells derived from Wharton’s Jelly of the umbilical cord: biological properties and emerging clinical applications.|
|Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C.|
|Curr Stem Cell Res Ther. 2013 Mar;8(2):144-55. Review.|
|PMID: 23279098 [PubMed – indexed for MEDLINE]|
|Proangiogenic features of Wharton’s jelly-derived mesenchymal stromal/stem cells and their ability to form functional vessels.|
|Choi M, Lee HS, Naidansaren P, Kim HK, O E, Cha JH, Ahn HY, Yang PI, Shin JC, Joe YA.|
|Int J Biochem Cell Biol. 2013 Mar;45(3):560-70. doi: 10.1016/j.biocel.2012.12.001. Epub 2012 Dec 12.|
|PMID: 23246593 [PubMed – indexed for MEDLINE]|
|Mesenchymal stem cells isolated from peripheral blood and umbilical cord Wharton’s jelly.|
|Trivanović D, Kocić J, Mojsilović S, Krstić A, Ilić V, Djordjević IO, Santibanez JF, Jovcić G, Terzić M, Bugarski D.|
|Srp Arh Celok Lek. 2013 Mar-Apr;141(3-4):178-86.|
|PMID: 23745340 [PubMed – indexed for MEDLINE] Free Article|
|Wharton’s jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: a preliminary report.|
|López Y, Lutjemeier B, Seshareddy K, Trevino EM, Hageman KS, Musch TI, Borgarelli M, Weiss ML.|
|Curr Stem Cell Res Ther. 2013 Jan;8(1):46-59.|
|PMID: 23270633 [PubMed – indexed for MEDLINE]|
|Perspectives of employing mesenchymal stem cells from the Wharton’s jelly of the umbilical cord for peripheral nerve repair.|
|Ribeiro J, Gartner A, Pereira T, Gomes R, Lopes MA, Gonçalves C, Varejão A, Luís AL, Maurício AC.|
|Int Rev Neurobiol. 2013;108:79-120. doi: 10.1016/B978-0-12-410499-0.00004-6. Review.|
|PMID: 24083432 [PubMed – indexed for MEDLINE]|
|Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis.|
|Hsieh JY, Wang HW, Chang SJ, Liao KH, Lee IH, Lin WS, Wu CH, Lin WY, Cheng SM.|
|PLoS One. 2013 Aug 22;8(8):e72604. doi: 10.1371/journal.pone.0072604. eCollection 2013.|
|PMID: 23991127 [PubMed – indexed for MEDLINE] Free PMC Article|
|Comparison of mesenchymal stem cells derived from fat, bone marrow, Wharton’s jelly, and umbilical cord blood for treating spinal cord injuries in dogs.|
|Ryu HH, Kang BJ, Park SS, Kim Y, Sung GJ, Woo HM, Kim WH, Kweon OK.|
|J Vet Med Sci. 2012 Dec;74(12):1617-30. Epub 2012 Aug 9.|
|PMID: 22878503 [PubMed – indexed for MEDLINE] Free Article|
|Hydrogen peroxide preconditioning enhances the therapeutic efficacy of Wharton’s Jelly mesenchymal stem cells after myocardial infarction.|
|Zhang J, Chen GH, Wang YW, Zhao J, Duan HF, Liao LM, Zhang XZ, Chen YD, Chen H.|
|Chin Med J (Engl). 2012 Oct;125(19):3472-8.|
|PMID: 23044308 [PubMed – indexed for MEDLINE] Free Article|
|Immune characterization of mesenchymal stem cells in human umbilical cord Wharton’s jelly and derived cartilage cells.|
|Liu S, Yuan M, Hou K, Zhang L, Zheng X, Zhao B, Sui X, Xu W, Lu S, Guo Q.|
|Cell Immunol. 2012 Jul-Aug;278(1-2):35-44. doi: 10.1016/j.cellimm.2012.06.010. Epub 2012 Jul 16.|
|PMID: 23121974 [PubMed – indexed for MEDLINE]|
|Human umbilical cord Wharton’s jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells.|
|Subramanian A, Shu-Uin G, Kae-Siang N, Gauthaman K, Biswas A, Choolani M, Bongso A, Chui-Yee F.|
|J Cell Biochem. 2012 Jun;113(6):1886-95. doi: 10.1002/jcb.24057.|
|PMID: 22234854 [PubMed – indexed for MEDLINE]|
|Comparison of human amniotic fluid-derived and umbilical cord Wharton’s Jelly-derived mesenchymal stromal cells: Characterization and myocardial differentiation capacity.|
|Bai J, Hu Y, Wang YR, Liu LF, Chen J, Su SP, Wang Y.|
|J Geriatr Cardiol. 2012 Jun;9(2):166-71. doi: 10.3724/SP.J.1263.2011.12091.|
|PMID: 22916064 [PubMed] Free PMC Article|
|Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients.|
|Ma L, Zhou Z, Zhang D, Yang S, Wang J, Xue F, Yang Y, Yang R.|
|Thromb Haemost. 2012 May;107(5):937-50. doi: 10.1160/TH11-08-0596. Epub 2012 Mar 8.|
|PMID: 22398715 [PubMed – indexed for MEDLINE]|
|Comparison of chemokine and receptor gene expression between Wharton’s jelly and bone marrow-derived mesenchymal stromal cells.|
|Balasubramanian S, Venugopal P, Sundarraj S, Zakaria Z, Majumdar AS, Ta M.|
|Cytotherapy. 2012 Jan;14(1):26-33. doi: 10.3109/14653249.2011.605119. Epub 2011 Nov 18.|
|PMID: 22091833 [PubMed – indexed for MEDLINE]|
|Wharton’s Jelly stem cells: future clinical applications.|
|Taghizadeh RR, Cetrulo KJ, Cetrulo CL.|
|Placenta. 2011 Oct;32 Suppl 4:S311-5. doi: 10.1016/j.placenta.2011.06.010. Epub 2011 Jul 6. Review.|
|PMID: 21733573 [PubMed – indexed for MEDLINE]|
|Neuronal plasticity of human Wharton’s jelly mesenchymal stromal cells to the dopaminergic cell type compared with human bone marrow mesenchymal stromal cells.|
|Datta I, Mishra S, Mohanty L, Pulikkot S, Joshi PG.|
|Cytotherapy. 2011 Sep;13(8):918-32. doi: 10.3109/14653249.2011.579957. Epub 2011 Jun 22.|
|PMID: 21696238 [PubMed – indexed for MEDLINE]|
|Wharton’s jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.|
|Anzalone R, Lo Iacono M, Loria T, Di Stefano A, Giannuzzi P, Farina F, La Rocca G.|
|Stem Cell Rev. 2011 Jun;7(2):342-63. doi: 10.1007/s12015-010-9196-4. Review.|
|PMID: 20972649 [PubMed – indexed for MEDLINE]|
|Immunomodulatory effect of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on lymphocytes.|
|Zhou C, Yang B, Tian Y, Jiao H, Zheng W, Wang J, Guan F.|
|Cell Immunol. 2011;272(1):33-8. doi: 10.1016/j.cellimm.2011.09.010. Epub 2011 Sep 29.|
|PMID: 22004796 [PubMed – indexed for MEDLINE] Free PMC Article|
Nova Cells Institute (NCIM) often gets emails from people who ask about stem cell and other therapies done elsewhere but which have little chance of turning things around for them. Here are some of these treatments along with comments by NCIM experts:
(1) Subcutaneous injections of stem cells to treat serious neurologic and other health challenges, including cancer. COMMENT: Subcutaneously injected stem cells may stimulate production of nerve growth factor or other compounds, but is an iffy way to stimulate healing or regeneration unless one is treating a problem very close to the injection site. Depending on the target tissue or organ, stem cells given by intravenous, intrathecal or other routes is more likely to have the desired therapeutic effect.
(2) Nova Cells hears from people who have been told that biochemical signals from injured or diseased tissues will attract infused stem cells. This is true but what they aren’t being told is that these signals fade over time or the injected or infuse stem cells typically do not respond fully to them. COMMENT: Nova Cells director of laboratory services, Dr. Abel Pena, created a nontoxic homing/signal amplification (or “beacon”) compound that stimulates damaged or diseased tissues to send out stronger stem cell attractive signals while simultaneously sensitizing stem cells to recognize and respond to these signals. This compound was dubbed, appropriately enough, the “Beacon Factor” and positively no one has it or anything like it but Nova Cells. You can read more about it by clicking this link.
3) Emails occasionally come in from people saying they have been offered some kind of stem cell or other therapy (for a serious or intractable condition) in Mexico or elsewhere for between $1,000-4,000 USD. COMMENT: The old sayings “If it sounds too good to be true, it is” and “caveat emptor” (Buyer beware) certainly applies here. What NCIM has turned up down through the years (with respect to these “medical blue plate specials”) are instances in which: (a) MDs and others gave patients far fewer cells than claimed. In one particular instance, an office worker in a so-called stem cell clinic reported actually seeing a doctor take a vial labelled as containing 5 million umbilical cord stem cells and placing a small quantity from this into each of ten other vials, then administering these to patients who had paid to get 5 million stem cells each; (b) Patients were given “live cell therapy” (embryonic cells from animals typically lambs) but were told they were getting human umbilical or other adult stem cells: (c) People with advanced, terminal cancer were given low cost treatments that had worked in lab dish or animal studies but bombed out in well designed & executed studies done in humans.
Doing medicine in Mexico is not cheap contrary to what some people think. Unfortunately, there are unscrupulous doctors and clinics that have come up with “cost cutting measures” (like those above) who do a grave disservice to the patients they purport to help.
Nova Cells is able to offer economically priced care, i.e., typically 30% less than other stem cell medicine operations, because it cut out the “middle men”, e.g., professional marketers and public relations people, and was able to get top flight MDs including surgeons on board who believe profits must take a backseat to getting people well. And, its head of laboratory services, Dr. Abel Pena (photo on right), who was trained (in part) by a leading US stem cell biologist, insists on processing & counting all stem cells himself and then priming or programming them (to become cell types that are more likely to effect healing or restoration in a given patient than unprimed stem cells). Dr. Pena personally handles all aspects of stem cell and Beacon Factor processing so as to insure that everything is done to the highest cGMP (manufacturing) standards and the patient is getting exactly what he or she paid for.
Nova Cells has assembled information on its stem cell medicine program including stem cell priming and its proprietary Beacon Factor in e-book form titled “Heroic Medicine” which is free at http://www.novacellsinstitute.com/pdf/Heroic%20Medicine.pdf
Stem cell homing makes a big difference in clinical outcomes. Watch this short video to learn more about how Nova Cells pulls this off.
Nova Cells Institute gets stem cells to target tissues using its Beacon Factor. Learn more by getting our FREE e-book “Heroic Medicine” (Click to download). Read about our successful stem cell treatments for spina bifida, cancer, stroke, dementia, autoimmune diseases, and more. Get your FREE e-book “Heroic Medicine” now!
If you ever played the game of darts or used a crossbow you know the goal is to hit your target. In the world of stem cell medicine the same holds true. Virtually all stem cell therapy clinics and hospitals infuse or inject stem cells and count on biochemical signals produced by damaged or diseased tissues to “get the darts” (stem cells) to target. This works in principle, yes, but likely winds up with more stem cells lodged in non-target tissues than in the tissues or organ needing healing or restoration. This diminishes responses and outcomes as you would expect.
But what if you switch on a homing system in the stem cells and amplify the signals in diseased or damaged tissues or organs? More “darts” or “biologic missiles” (stem cells) will hit their mark!
No stem cell clinic or such anywhere has a biologic “guidance & homing signal amplification system” that helps get stem cells to target. None, that is, but Nova Cells Institute which pulls this off thanks to its proprietary Beacon Factor. You can read more about the Beacon Factor by clicking this link.
You will also find information on the Beacon Factor in Nova Cells Institute’s just published e-book titled “Heroic Medicine”, which is free for downloading at http://www.novacellsinstitute.com/pdf/Heroic%20Medicine.pdf
October is #BreastCancerAwareness Month. Are you aware that Nova Cells pioneered a highly successful cancer treatment approach that has put 50% of those treated with advanced cancer into full remission, and the rest in partial remission and oncostasis (No cancer progression)? Read more at http://www.novacellsinstitute.com/articles/DONOR-GRANULOCYTE-BASED-TMT-SAVING-END-STAGE-CANCER-PATIENTS-April-29-2014.pdf
Learn more about each of the disorders below by either following the link, or emailing or placing a call. Nova Cells has successfully treated many other conditions so if you do not see your particular challenge here, just ask us about our experience with it!
ALS (Lou Gehrig’s disease) – Email NCInfodesk@gmail.com for specifics or call 1-562-916-3410
Autism – Email NCInfodesk@gmail.com for specifics or call 1-562-916-3410
Cancer Cancer (End-stage & advanced too): http://www.novacellsinstitute.com/cancer-stem-cell-therapy.html
Cerebral Palsy – https://ncimx.wordpress.com/?s=Cerebral+Palsy
Chronic Fatigue Syndrome (CFS) – Email NCInfodesk@gmail.com for specifics or call 1-562-916-3410
Dementia/Lewy Body Dementia – https://ncimx.wordpress.com/?s=Dementia
Epilepsy/Other Seizure Disorders – https://ncimx.wordpress.com/?s=Seizure
Fibromyalgia – Email NCInfodesk@gmail.com for specifics or call 1-562-916-3410
Fibrosis – Email NCInfodesk@gmail.com for specifics or call 1-562-916-3410
Multiple sclerosis – https://ncimx.wordpress.com/?s=multiple+sclerosis
Parkinson’s Disease – See alzheimer’s-dementia
Spina Bifida – https://ncimx.wordpress.com/?s=Spina+Bifida
Spinal Cord Injury/Paralysis – https://ncimx.wordpress.com/?s=spinal+cord+injury
Traumatic Brain Injury – Email NCInfodesk@gmail.com for specifics or call 1-562-916-3410 begin_of_the_skype_highlighting
August 1 is #WorldLungCancerDay. This insidious form of cancer is one Nova Cells has had considerable success in treating. You can read more about the NCIM cancer program at http://www.novacellsinstitute.com/cancer-stem-cell-therapy.html
If you’d like specifics on advanced and end-stage cancer turnarounds* you should contact Grace Odgers, Ph.D. cand. using the information below:
Want to know more about NCIM and its pioneering immunologic treatment program for cancer? Call NCIM’s US information line at 1-562-916-3410 or email NCIM patient care facilitator/educator Grace Odgers, Ph.D. cand., by e-mail at email@example.com.
* Many, many cancer case histories have yet to be written up. Grace has specifics and will gladly share this with anyone who calls or emails her.
NEURONAL REPAIR & NEW NERVE CELL FORMATION
TRAUMATIC BRAIN INJURY
AFTER VIEWING THE VIDEO, CLICK THIS LINK: http://goo.gl/seF7SX
On Sunday December 7 (2014) CBS’s famed 60 Minutes devoted a thirteen minute segment titled “Disrupting Cancer” to physician and billionaire businessman Patrick Soon-Shiong, MD‘s advocacy and use of the rapid gene sequencing of tumor cells to help zero in specific drugs or other agents that will eradicate them. Later the same day, Forbes’s writer Matthew Herper published an article in which he stated something virtually everyone doing cancer work knows, namely that “Everyone is looking to use DNA sequencing to better pick cancer drugs. And in some ways, Soon-Shiong is an odd person to pick as a spokesperson for this, because he’s just getting started. ” (Here Is What ’60 Minutes’ Didn’t Tell You About The Billionaire Who Is Trying To Disrupt Cancer Care).
This is not to say that with Dr. Soon-Shiong’s deep pockets and army of computer experts and researchers he will not wind up making major inroads in this area of biomedicine. And with cancer striking so many, progress is welcome whether it comes out of a one person lab or a research enterprise that fills buildings or is stretched across many continents.
Nova Cells is no stranger to finding ways to “disrupt cancer”. It has, in fact, focused on a treatment approach that combines attacking tumors using donor immune cells (from healthy young people) and specific compounds that gum up the inner machinery in cancer cells while leaving healthy cells. It has been a spectacularly successful quest that started with the treatment of a 71 year old gentleman from the Pacific Northwest who was in the last throes of end-stage prostate cancer that had spread into his liver and bones. He was, in fact, so bad off that NCIM doctors thought he might not live more than a handful of days, at best. But, like so many people struggling with cancer, he was a spirited fighter who simply would not entertain abandoning hope until, as he put it, “I take my last breathe”.
This determined chap knew the score going into treatment, namely that he was volunteering to undergo something very experimental in nature. But he was resolutely committed to “fighting the good fight”, even if this pitched battle proved his last. Seeing his determined spirit, the MDs set about stabilizing him to help insure he could handle the biological blitzkrieg (lightening war) that NCIM’s experimental tumor-killing method was expected to unleash in his body.
Three days later the doctors began daily treatments using cancer-fighting cells (called granulocytes) that had been previously isolated from the blood of many young, healthy volunteers and then combined and infused by intravenous (IV) means. In addition, he was to be given intentionally HLA mismatched umbilical cord stem cells.
If the treatment worked as anticipated, the donor granulocytes would attack the tumors and also send a “wake up call” to the immune system, i.e., alert the fellow’s own immune cells that something alien was present which they would then attack (One problem in cancer is that tumors send out biochemical signals that suppress the sufferer’s own innate tumor-fighting cells). In addition, the HLA mismatched umbilical cord blood stem cells would be attracted by growth factors secreted by the tumors, attach to them, and then be attacked by the patient’s own immune cells which would react to them as a foreign presence.
The outcome? He did had a mild immune reaction (rash) that was easily suppressed using an IV antihistamine. This is how NCIM’s own patient care coordinator, Grace Pena, Ph.D. cand., summed up what transpired:
“Within three days his face was pinkish and his hands were getting pink. He was eating so well that the staff could not believe it. After the 7th primed donor granulocyte treatment he was walking 1/2 mile around the hospital, and feeling great. He was feeling so good in fact that he decided to return to his home state of Washington to finish up a million dollar real estate deal. NCIM doctors and staff protested wanting him to finish the entire course of therapy but he was adamant about getting home, but promised to return and complete his care once his real estate deal was completed. This he did. By October his US oncologist reported that his PSA is 1.1, his prostate is smaller than a normal 20 year olds, and he could find no cancer at all. Also, his Alkaline Phosphatase level which was about 2,000 during his treatment had dropped to something around 89.”
This fellow remains in full remission to this day.
Following this exciting clinical success, other end-stage cancer patients were treated (prostate, breast, lung, others) using the same method. Fifty percent (50%) experienced tumor shrinkage (partial remission) while the rest (50%) went into full remission.
In addition, other cancer-fighting measures were tested both alone and in combination with the donor granulocytes & cord blood stem cells (Gr-UCSC). Those that resulted in tumor shrinkage or obliteration when used alone, as well as those that bolstered the anti-cancer impact of the Gr-UCSCs were retained.
Among these were two chemical compounds that throw a monkey wrench into the tiny power-generating factories (mitochondria) in tumor cells but do not adversely affect normal cells. They are, in technical parlance Patrick Soon-Shiong, MD, selective for malignant cells.
NCIM also selectively utilizes a unique injectable protein that amplifies the cancer-fighting activity of a patient’s own macrophages.
Returning now to that 60 Minutes segment: Dr. Soon-Shiong beamed about tackling cancer at an immunological level. Nova Cells doctors and staff wish him well in this quest, but can’t help adding that in many ways we left the starting gate years ago and are “already there” (That is, have made demonstrable progress and enjoyed great success).
If you’d like to know more about NCIM’s cancer treatment method, just click these links:
You can also email or call NCIM:
Do you wonder what sets NCIM apart from other stem cell medicine operations? We have summarized the major differences in a simple chart which you can access by clicking the image below or by clicking or keying in http://bit.ly/18Sf87t
February-March 2012: A Mexican national, age 58, with advanced prostate cancer that had spread to his liver and bones (femur and others) was treated using the core NCIM approach. He had had no prior conventional cancer care such as chemotherapy or radiotherapy. At the time of his initial infusion of donor granulocytes his PSA level was almost 1000 and he was very thin, pale, was jaundiced, and could not sit on a sofa comfortable due to the massive size of his tumor-laden prostate gland. In the 2 months since his series of donor granulocytes treatments his PSA has plummeted to 47, his jaundice is gone, and the tumors throughout his body are shrinking very rapidly.
7-22-11: A gentlemen with advanced disseminated prostate cancer with metastases to the bone flew into Mexico a few days ago (from Croatia) to begin the NCIM cancer-fighting program. He has had 2 treatments to-date and has already experienced his color return to normal and strength return to his arms. The attending MDs and RNs are flabbergasted, as is this fellow’s daughter who flew in with him. Though these are just initial responses they closely parallel those seen in the 1st patient and for this reason have everyone involved quite excited and enthused! More to follow as this chap gets further into his 3 week course-of-therapy.
8-26-2011: The patient returned to his home in Eastern Europe and continues to improve, according to family and close associates. NCIM is now awaiting receipt of a medical assessment from his primary care physician.
1-12-2012: The patient’s daughter sent an email to NCIM indicating that her father has no pain whatsoever and is off of all morphine (He was utterly dependent on morphine to control intractable cancer-related pain at the time of his Nova Cell Institute treatment in 2011.) NCIM staffers are trying to arrange to get a status update from his primary care MD in Croatia.
The very first cancer patient to be treated as part of NCIM’s unique treatment program (March 2011) is now in full remission. You can read about the program by clicking this link: http://bit.ly/rpLikU. NCIM’s Grace Pena offered this firsthand account of this man’s course of care and response:
“One 71 year old gentleman with cancer of the prostate, metastasized to the liver and bone was treated almost 8 months ago. When he arrived at NCIM’s contracted hospital he was in a very sad state, i.e., his legs were all swollen, his PSA was in the neighborhood of 650, he had no energy, a deadly yellowish greenish color to his face and was naturally feeling horrible. On top of all this he was in great pain and could not urinate. The doctors first controlled his swelling and drained out 3-4 liters of urine from his bladder. After a week of stabilizing him (he was literally dying), the NCIM immunological treatment program was started. Within three days his face was pinkish and his hands were getting pink. He was eating so well that the staff could not believe it. After the 7th primed donor granulocyte treatment he was walking 1/2 mile around the hospital, and feeling great. He was feeling so good in fact that he decided to return to his home state of Washington to finish up a million dollar real estate deal. NCIM doctors and staff protested wanting him to finish the entire course of therapy but he was adamant about getting home, but promised to return and complete his care once his real estate deal was completed. This he did. By October his US oncologist reported that his PSA is 1.1, his prostate is smaller than a normal 20 year olds, and he could find no cancer at all. Also, his Alkaline Phosphatase level which was about 2,000 during his treatment had dropped to something around 89.”
UPDATE 3-27-2012: Patient #1 is still in full remission.
UPDATE 8-2-2015: Patient #1 is still in full remission!